BioWorld. Link to homepage.
BioWorld
BioWorld MedTech
BioWorld Asia
BioWorld Science
Data Snapshots
BioWorld
BioWorld MedTech
Infographics: Dynamic digital data analysis
Special reports
Aging
Alzheimer's disease
Artificial intelligence
Biosimilars
China CAR T
Coronavirus
Infographics: Dynamic digital data analysis
Israel
IVDs on the rise
Radiopharmaceuticals
Rise of obesity
Top Biopharma Trends of 2023
Top Med-tech Trends of 2023
Top Preclinical Trends of 2023
Premium reports
BioWorld Financings Reports
Disease Incidence & Prevalence Summaries
BioWorld. Link to homepage.
sign in
Sign Out
My Account
Subscribe
BioWorld - Monday, May 13, 2024
See today's BioWorld Asia
Home
» Merck joins SHP2 players in expanded Astex-Taiho deal
To read the full story,
subscribe
or
sign in
.
Merck joins SHP2 players in expanded Astex-Taiho deal
Jan. 19, 2021
By
Nuala Moran
No Comments
LONDON – Merck & Co. Inc. has become the latest pharma company to in-license a SHP2 small-molecule program, as the rush to find companion pieces for KRAS oncogene inhibitors heats up.
BioWorld Asia
Deals and M&A
Cancer